Αποτελέσματα Αναζήτησης
Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biomedical companies. With more than $1B of capital raised, we support innovative companies from seed to growth stage.
- Portfolio
Portfolio - Prospect Venture Partners
- News
Connect with Prospect Ventures: Prospect Ventures on...
- Russell Hirsch
Russell is a Managing Director of Prospect Venture Partners....
- David Schnell
David Schnell is a co-founder and Managing Director of...
- Alex Barkas, In Memoriam
Alex Barkas, In Memoriam - Prospect Venture Partners
- What We Do
We have the requisite skills, industry contacts, and...
- What We've Achieved
What We've Achieved - Prospect Venture Partners
- Contact
Contact - Prospect Venture Partners
- Portfolio
At Prospect Venture Partners, we partner with extraordinary management teams and invest where we see a track record of innovation. Our team has more than two decades of experience and deep industry contacts to help guide outstanding executives leading early stage companies.
David has invested in over 60 venture-backed companies with his partners and built a strong investment track record by supporting talented entrepreneurs launch and grow compelling new businesses across a variety of industries. He has led numerous successful investments for Prospect in biotechnology.
PALO ALTO, CA - Prospect Venture Partners, a venture capital firm dedicated to investing in medical technology and life science companies, today announced the closing of its third fund, Prospect Venture Partners III.
David Schnell is a co-founder and Managing Director of Prospect Venture Partners, a venture capital firm dedicated to investing in and supporting emerging biomedical companies.
We have the requisite skills, industry contacts, and experience to advise and assist outstanding executives who are capable of leading early stage companies. The partners at Prospect Ventures have a strong entrepreneurial track record in creating new companies.
Prospect [Venture Partners] is looking at all health care segments, but it's concentrating on target validation for genomic platform companies, early-stage medical devices and information services in health care.
